A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

Eligibility Criteria

• * Participants must have a pre-existing diagnosis of HF NYHA FC II to IV.
• * Participants must be on stable HF standard of care medication for at least 4 weeks prior to consent and during the Screening period.
• * Minimum body mass index (BMI) of 18 kilograms per meter square (kg/m\^2) at Screening.
• * For female participants, the participant must not be pregnant or lactating and must be of non-childbearing potential.
• * All male participants should refrain from fathering a child or donating sperm until 3 months after the final study Follow-up Visit. Non-sterilised male participants should avoid fathering a child either by true abstinence or use of a condom for all sexual intercourse with a female partner of childbearing potential from the first dose until 3 months after the final Follow-up Visit.
• * Historical or current evidence of a clinically significant disease or disorder including, but not limited to:
• 1. Myocardial infarction, stroke, transient ischaemic attack, coronary artery bypass grafting, or percutaneous coronary intervention within 12 weeks prior to consent or transcatheter structural heart interventions or cardiac valve surgery within 6 months prior to consent.
• 2. Sarcoidosis, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic (obstructive) cardiomyopathy.
• 3. History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency.
• 4. Amyloidosis, Fabry disease, or haemochromatosis.
• 5. Pericardial disease (i.e., visually significant white pericardium on echocardiogram).
• 6. Known coagulation disorders.
• 7. Current diagnosis of active hepatitis.
• 8. Severe pulmonary disease that is not expected to improve over time, as assessed by the investigator.
• 9. Decompensated HF or any cardiopulmonary hospitalisation within 4 weeks prior to consent or during the Screening period.
• 10. History of active malignancy within 2 years, except for fully excised or treated basal cell carcinoma, or ≤ 2 squamous cell carcinomas of the skin and participants who are under investigation for breast or cervical cancer, including participants with a pap smear of grade ≥ 3.
• * History of hypersensitivity to AZD5462 or any component of AZD5462 drug product.
• * Known history of drug or alcohol abuse within 24 months of Screening.
• * Congenital long QT syndrome or history of QT prolongation associated with other medications that required discontinuation of that medication.
• * Cardiac ventricular arrhythmia that requires treatment.
• * History of or anticipated heart transplant.
• * Current or planned cardiac resynchronization therapy/bi-ventricular pacemaker or mechanical assist device implantation.
• * Any planned highly invasive cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter etc).
• * Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody at Screening.
• * Known to have historically tested positive for Human Immunodeficiency Virus.